EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

How I reduce and treat posttransplant relapse of MDS

Alain Mina iD, Peter L Greenberg iD, H Joachim Deeg

Blood · 2024

DOI: 10.1182/blood.2023023005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, 2024. Verfasst von Alain Mina und 2 weiteren Autor:innen. Beteiligte Einrichtung: Myeloid Malignancies Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for patients with high-risk myelodysplastic syndromes (MDS). Advances in conditioning regimens and supportive measures have reduced treatment-related mortality and increased the role of transplantation, leading to more patients undergoing HSCT. However, posttransplant relapse of MDS remains a leading cause of morbidity and mortality for this procedure, necessitating expert management and ongoing results analysis. In this article, we review treatment options and our institutional approaches to managing MDS relapse after HSCT, using illustrative clinical cases that exemplify different clinical manifestations and management of relapse. We address areas of controversy relating to conditioning regimen intensity, chemotherapeutic bridging, and donor selection. In addition, we discuss future directions for advancing the field, including (1) the need for prospective clinical trials separating MDS from acute myeloid leukemia and focusing on posttransplant relapse, as well as (2) the validation of measurable residual disease methodologies to guide timely interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansProspective StudiesTransplantation, HomologousTransplantation ConditioningRecurrenceChronic Disease

Autor:innen und Institutionen

  • Myeloid Malignancies Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
  • Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA.
  • Fred Hutchinson Cancer Center, Seattle, WA.

ORCID-Profile: Alain Mina, Peter L Greenberg

Zitieren

APA

Mina, A., Greenberg, P. L., & Deeg, H. J. (2024). How I reduce and treat posttransplant relapse of MDS. Blood. https://doi.org/10.1182/blood.2023023005

Vancouver

Mina A, Greenberg PL, Deeg HJ. How I reduce and treat posttransplant relapse of MDS. Blood. 2024. doi:10.1182/blood.2023023005

BibTeX
@article{Mina2024,
  author = {Mina, Alain and Greenberg, Peter L and Deeg, H Joachim},
  title = {How I reduce and treat posttransplant relapse of MDS},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023023005}
}
Kostenlos starten →